Aurobindo Pharma arm gets marketing authorisation in UK for Zefylti
Hyderabad: CuraTeQ Biologics s.r.o., a wholly owned step-down subsidiary of Aurobindo Pharma Ltd, has obtained marketing authorisation from UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for Zefylti, its filgrastim biosimilar version.
Earlier this year, in February, the European Commission (EC) has granted marketing authorization in the European Union (EU) for Zefylti, to CuraTeQ Biologics s.r.o.., as previously reported by Medical Dialogues.
This is CuraTeQ’s second biosimilar to be approved by MHRA after the approval of Bevqolva in December 2024.
Zefylti is intended for the treatment of neutropenia and the mobilisation of peripheral progenitor cells (PBPCs).
Read also: Aurobindo Pharma arm gets marketing authorisation for Zefylti in EU
CuraTeQ Biologics Private Limited, a wholly owned subsidiary of Aurobindo Pharma Limited, is a global biopharmaceutical company headquartered in Hyderabad, India. It is focused on developing biosimilars for the treatment of various cancers and autoimmune diseases. CuraTeQ's pipeline consists of fourteen biosimilars, primarily targeting the immunology and oncology segments. It has end-to-end capabilities in producing a full range of products from bulk drug substance to fill-finish and packaged drug products.
